CA-LONG-TALE-GAMES
18.4.2024 14:01:33 CEST | Business Wire | Press release
Long Tale Games (LTG) announces the Steam relaunch of Life is Feudal: MMO. To show appreciation to the game's community, the publisher is launching a special event aimed at the game's original players, the Balance Restoration Campaign. Players who have made any purchases during the previous Life is Feudal: MMO round will receive special LiF Coins that can be exchanged for a subscription to the game.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240418169927/en/
(Graphic: Business Wire)
Since the relaunch in June 2023, Life is Feudal: MMO has transitioned to a subscription-based model, removing all pay-to-win features. This shift ensures a level playing field for all players, fostering fairness as success in the game now fully depends on the player's skill and effort, creating a more engaging environment. Until now, the game has only been distributed through the publisher's (LTG.com) own personal gaming platform. However, with this launch, it is now expanding its presence to other stores, starting with Steam.
Evgenii Romin, Publishing Director at Long Tale Games, expressed his enthusiasm for the forthcoming relaunch and the accompanying campaign by saying, "We are incredibly excited to introduce 'Life is Feudal: MMO' to a broader audience via Steam. In addition, we're eager to show our gratitude towards our community through the balance restoration campaign. This endeavor demonstrates our appreciation for our players' support and mirrors our dedication to ensuring a fair and rewarding gaming experience."
Life is Feudal: MMO has been significantly refined through relentless development, targeted rebalancing, and the elimination of bugs while maintaining a strong bond with its community, with a special nod to the contributions of modders. The game has experienced a renaissance with over 150 updates to its content, including new items, buildings, professions, and gameplay mechanics, along with the introduction of much-anticipated features like in-game voice chat, anti-cheat systems, and additional content. These advancements and captivating events, such as the King of the Hill competition, have profoundly enriched the gaming experience. Thank you to the players and the MMO community for their dedication to our favorite real-life Medieval simulator.
Looking ahead, the roadmap for Life is Feudal: MMO includes major updates inspired by the community's feedback, such as a new map and many game improvements scheduled for mid-2024. This strategy underscores LTG's commitment to developing Life is Feudal: MMO in close cooperation with the community.
What is Life is Feudal: MMO?
Life is Feudal: MMO is a sandbox MMORPG set in a gritty medieval world called Abella. Players find themselves in this strange new world with no memory of their past and must quickly learn the basics of survival, from hunting and gathering to finding allies who will support them in their time of need. As their journey progresses, players will be able to learn new skills that allow them to craft intricate weapons, construct buildings, and even establish towns, castles, and mighty fortresses.
Whether players choose to band together in guilds and march out on epic wars of conquest or master the art of solo survival, the game offers endless opportunities for explorations and conquest, no matter what path they set out on.
About Long Tale Games
Long Tale Games (LTG) is a multiverse publisher set on reinvigorating legendary games with fresh energy and employing innovative monetization and user acquisition techniques. With a diverse portfolio that includes everything from classic to web3 games, LTG leverages industry expertise to channel, port, further develop, and support the marketing of hidden gems and classics, ensuring each project gets a tailored approach. At its core, LTG is powered by dedicated industry veterans who believe in a community-driven strategy, involving players in the development process to breathe new life into every game, proving their dedication to reviving beloved titles and fostering the growth of new ventures in the gaming world.
For additional information and to learn more, please visit corp.ltg.com
The monetization model: $14.99 monthly subscription, with a 7-day free trial for new users and 30 days for owners of the original Life is Feudal: MMO on Steam.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240418169927/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom